PAVA x RÖDL: FDA Strategy for HealthTech Companies

​„Taking your HealthTech company to the US? Prepare for the decisions that matter"

​FDA Strategy | Impact on Fundraising and M&A

​Taking a high-growth company in HealthTech, MedTech, Medical Devices or Diagnostics to the US involves more than regulatory approval alone.

​FDA strategy, clinical evidence and regulatory timing can directly affect funding needs, runway and strategic options. At the same time, founders and management need to consider financing, the investor entering the cap table and the company’s corporate and transaction setup.

​Join Rödl and Pava Partners on October 20, 2026, during Frontiers Health in Berlin, for a practical evening session designed for a selected group of founders, entrepreneurs, industry-leaders and investors. We will bring together FDA and regulatory expertise, Corporate & M&A advice, and financing and transaction experience.

​The evening

​🕡 18:30 to 19:00 | Welcome and arrival (Pava Partners Office)

​🎤 19:00 to 19:45 | Expert sessions

​→ 30 min | Rödl: Building US readiness: FDA strategy and M&A legal considerations

​→ 15 min | Pava Partners: What investors and potential buyers will look for

​🤝 19:45 to 22:00 | Networking, drinks and finger food

​What we will discuss

​→ FDA & US readiness: How do the FDA pathway, clinical requirements and timing affect route to market, funding needs and valuation?

​→ Financing & transaction strategy: How does US readiness influence fundraising and the investor universe – and what do investors and potential buyers look for?

​→ Strategic investor or financial investor? Is the highest valuation necessarily the best offer – and how can today’s choice affect the next financing round and a future exit?

​→ Corporate & M&A: How can strategic investor rights affect future financing and exit options?

​Looking forward!

​Rödl and Pava Partners